Data Management and Coordinating Center: Rare Diseases Clinical Research Network

数据管理和协调中心：罕见病临床研究网络

• 批准号: 9804408
• 负责人: Eileen Catherine King
• 金额: $ 556.49万
• 依托单位: CINCINNATI CHILDRENS HOSP MED CTR
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-08-05 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9804408
• 关键词: Address; Adoption; Affect; American; Caring; Categories; Characteristics; Child; Child Health; Childhood; Chronic; Clinical; Clinical Research; Clinical Trials; Clinical Trials Design; Collaborations; Communication; Communities; Complex; Country; Data; Data Analyses; Data Element; Decision Making; Developed Countries; Developing Countries; Diagnosis; Disease; Ecosystem; Ensure; Epidemiology; Esapent; Etiology; European Union; Face; Family; Functional disorder; Genetic; Genetic Diseases; Geography; Goals; Growth; Health; Individual; Informatics; Information Systems; Infrastructure; Institution; Investments; Knowledge; Leadership; Learning; Libraries; Life; Measures; Methods; Natural History; Observational Study; Outcome; Pathway interactions; Patients; Persons; Phase; Phenotype; Population; Privatization; Process; Production; Protocols documentation; Public Health; Rare Diseases; Readiness; Regulation; Reproducibility; Reproducibility of Results; Research; Research Design; Research Personnel; Resource Sharing; Resources; Secure; Standardization; Structure; System; Technology; Translating; Translational Research; Universities; clinical practice; comparative effectiveness; data integration; data management; data sharing; disease classification; effective therapy; effectiveness research; evidence base; implementation strategy; improved; infancy; knowledge base; meetings; novel strategies; phase III trial; programs; rare genetic disorder; user-friendly

Project Summary/Abstract Rare diseases (RD) and disorders collectively affect about 25 million Americans. RD research and care face common challenges, including: 1) insufficient knowledge about the etiology, pathophysiology, natural history and epidemiology of the diseases; 2) inadequate or non- uniform case definition and disease classification systems that make diagnosis and epidemiologic assessment difficult; 3) insufficient understanding of the determinants of multiple phenotypes and the relationships between genetic variance and phenotypic manifestations; 4) rarity and geographic dispersion of cases that hampers both access to qualified care and participation in research; 5) a dearth of clinically proven, safe and effective treatments; and 6) inadequate private investment into RD research and treatment. In the U.S., the Rare Diseases Act of 2002 authorizes the Office of Rare Disease Research to recommend a research agenda and promote coordination and cooperation among research programs. The Rare Diseases Clinical Research Consortia (RDCRC) that comprise the Rare Diseases Clinical Research Network (RDCRN) advance the diagnosis, management, and treatment of RDs to enhance clinical trial readiness. The RDCRN Data Management and Coordinating Center (DMCC) must provide state-of-the-art informatics, statistical and epidemiological expertise in clinical research study design and data management technology and processes, in order to guarantee the production of evidence that can support the progression of clinical and translational research (CTR) from Phase I through Phase III trials to adoption within standard clinical practice. To achieve the goal of enhancing clinical trial readiness throughout the RDCRN, we will establish the DMCC at Cincinnati Children’s and the University of Cincinnati with the following Specific Aims: 1): To advance the methods and the practice of RD CTR; 2) To develop and maintain a leading-edge, shared knowledge base for RD CTR; and 3) To establish the RDCRN as a globally connected resource for improving RD CTR across the entire RD ecosystem. We expect to accomplish these Aims by promoting collaboration and trial readiness, engaging patients and families, and creating an “Esprit de Corps” for the RDCRN, through the adoption of Learning System principles. Our proposed DMCC brings a unique combination of world-class expertise, outstanding infrastructure, state-of-the-art technology and enthusiastic institutional support. This winning combination will accelerate scientific discovery and understanding across the network, which will bring new treatment options to trial, ultimately translating into improved health and wellness for RD patients and their families worldwide.

项目摘要/摘要 罕见疾病(RD)和疾病总共影响了大约2500万美国人。研发研究 和护理面临共同的挑战，包括：1)对病因知识不足， 疾病的病理生理学、自然病史和流行病学；2)不适当或不适当 统一的病例定义和疾病分类系统，以作出诊断和 流行病学评估困难；3)对多发性硬化症的决定因素认识不足 表型及其遗传变异与表型表现的关系；4) 阻碍获得合格护理的病例的稀有性和地理分布 参与研究；5)缺乏经临床证实的安全有效的治疗方法；6) 对研发和治疗的私人投资不足。在美国，罕见的疾病 2002年法案授权罕见疾病研究办公室推荐研究议程 促进研究项目之间的协调与合作。罕见的疾病 组成罕见疾病临床研究的临床研究联盟(RDCRC) 网络(RDCRN)推进RDS的诊断、管理和治疗，以增强 临床试验准备就绪。RDCRN数据管理协调中心(DMCC)必须 在临床研究中提供最先进的信息学、统计学和流行病学专业知识 研究设计和数据管理的技术和流程，以保证 产生可支持临床和转化性研究进展的证据 (CTR)从第一阶段到第三阶段试验，再到在标准临床实践中采用。至 为了实现在整个RDCRN中加强临床试验准备的目标，我们将建立 辛辛那提儿童和辛辛那提大学的DMCC有以下具体内容 目标：1)推进研发CTR的方法和实践；2)开发和维护 研发中心的前沿共享知识库；以及3)将研发中心建立为 全球互联资源，用于提高整个研发生态系统的研发CTR。我们预计 通过促进协作和试验准备，吸引患者和 家庭，并通过采用学习，为RDCRN创建“团队精神” 系统原则。我们建议的DMCC提供了世界级专业知识的独特组合， 卓越的基础设施、最先进的技术和热情的制度支持。这 成功的组合将加速整个网络的科学发现和理解， 这将带来新的治疗选择进入试验，最终转化为改善健康和 为世界各地的RD患者及其家人提供健康保障。